Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 10/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.62 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4354262 | 1.00 | MEN1 (0.62) | MEN1KMT2AMCHR1GAAGFER | |
| SCHEMBL4351655 | 0.88 | MEN1 (0.80) | MEN1KMT2AMCHR1GAAGFER | |
| SCHEMBL4351654 | 0.88 | MEN1 (0.80) | MEN1KMT2AMCHR1GAAGFER | |
| SCHEMBL4364816 | 0.84 | MEN1 (0.62) | MEN1KMT2AMCHR1GAAGFER | |
| SCHEMBL4364812 | 0.84 | MEN1 (0.62) | MEN1KMT2AMCHR1GAAGFER | |
| SCHEMBL4348827 | 0.81 | MEN1 (0.76) | MEN1KMT2AMCHR1GAAGFER | |
| SCHEMBL4348830 | 0.81 | MEN1 (0.76) | MEN1KMT2AMCHR1GAAGFER | |
| SCHEMBL4350528 | 0.81 | MEN1 (0.66) | MEN1KMT2AMCHR1GAAGFER | |
| SCHEMBL4350531 | 0.81 | MEN1 (0.66) | MEN1KMT2AMCHR1GAAGFER | |
| SCHEMBL4350796 | 0.80 | MEN1 (0.62) | MEN1KMT2AMCHR1GAAGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1890695-B1 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | GRUENENTHAL GMBH (DE) | 2013-02-20 | — | — | EP | claimed |
| US-20090215758-A1 | Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs | GRUENENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215758-A1 | Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs | ABCB1, ABCG2, SLC5A2 | MEN1 1725/4885KMT2A 3923/4885MCHR1 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.